Friday, September 18, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchsemaglutidetype 2 diabetesneoplasmsmeta-analysis

Meta-analysis links semaglutide to modestly higher overall neoplasm risk

Pooled data from 19 randomized trials found no significant association with malignant neoplasms, with the odds ratio at 1.12 and p=0.054.

PR
By Priya Raman · Science Reporter
Sep 2 20:00 ETSource: Frontiers in pharmacology

The wire

  1. 01Nineteen RCTs from 2016 to 2025 covering 38,160 type 2 diabetes patients gave an odds ratio of 1.19 (95% CI 1.07-1.32) for overall neoplasms and 1.28 (1.02-1.61) for benign neoplasms with subcutaneous or oral semaglutide.
  2. 02The authors urge clinical awareness of potential neoplastic risk in patients on long-term semaglutide for glycemic control.
  3. 03Trial durations ran 26 to 156 weeks, too short to settle oncologic questions; the malignant-neoplasm signal did not reach significance and longer RCTs are called for.

From the source

Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Frontiers in pharmacology · 2026 · Zhong Y, Tan X, Zhang L et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42757217/